Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
Dana-Farber Researchers Find Blood Test Could Guide Future Treatment in Ewing Sarcoma
Expand Treatment Options for Patients with Peritoneal Metastases With an Early Cytoreduction Surgical Evaluation
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
Rare Inherited EGFR Mutation Linked to Dramatically Increased Lung Cancer Risk
Dana-Farber’s Edward Chouchani, PhD, selected as a 2026 Blavatnik National Award finalist
The Storied Career Of Clinical Physicist Dr. Charlie Ma: From Philadelphia To Cancer Centers Worldwide
Building a System of Focused Care for Lobular Breast Cancer
Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027
Dana-Farber Science Backs Development of Targeted Therapy for Rare GIST Cancer
Targeting CDK2 Could Boost Immunotherapy Response in Patients With a Wide Range of Cancers, According to Dana-Farber Science
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
Redefining Treatment Timelines for Platinum-Resistant Ovarian Cancer
FDA Approves First CELMoD Agent, with Dana-Farber Helping Advance its Development
Dana-Farber Investigators Develop Protein Degrader Discovery Platform and Find First-in-Kind Metabolically Activated Molecular Glue Degrader
Showing 1 - 15 of 1091 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...73 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
